爱普列特治疗良性前列腺增生临床疗效观察

目的:研究观察爱普列特治疗BPH的疗效和安全性.方法:60例患者分为两组,试验组30例,服用爱普列特每天两次,每次5 mg,对照组30例,服用保列治每天一次,每次5 mg,疗程6个月.结果:给药3个月后,爱普列特和保列治有效率分别为56.7%和60.0%,6个月后有效率分别为86.7%和90.0%,两组相比均差异无统计学意义(P＞0.05).不良反应发生率爱普列特组为10.0%(3/30),保列治组为13.3%(4/30),两者相比差异无统计学意义(P＞0.05).结论:爱普列特可明显改善BPH患者临床症状,不良反应发生率低,疗效和耐受性与保列治类似,是一种安全有效的治疗BPH的药物.

The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia

Objective:To study the efficacy and safety of epristeride in the treatment of benign prostatic hyperplasia(BPH) using an opened randomized controlled trial.Methods:60 BPH patients were enrolled in the trial,30 of which were administered 5 mg epristeride twice daily for 180 days,and the rest were administered 5 mg proscar daily for 180 days as well.Results:After 3 months therapy,the effective rate of epristeride and proscar was 56.7% and 60.0% respectively,and 6 months later,the rate was 86.7% and 90.0% respectively.There was no statistical difference between the effective rate of epristeride and proscar(P>0.05),neither did in the adverse effect rate(epristeride10.0% vs.proscar 13.3%,P>0.05).Conclusions:Epristeride could greatly relieve the clinic symptoms of BPH patients and adverse effects rarely occurred,which is an effective and safe drug for the treatment of BPH compared with proscar.